Publicaciones

Línea Desarrollo de vacunas

  • Diaz-Valdes, N., L. Manterola, V. Belsue, J. I. Riezu-Boj, E. Larrea, I. Echeverria, D. Llopiz, J. Lopez-Saga- seta, H. Lerat, J. M. Pawlotsky, J. Prieto, J. J. Lasarte, F. Borras-Cuesta, and P. Sarobe. 2011. Improved den- dritic cell-based immunization against hepatitis C virus using peptide inhibitors of interleukin 10. Hepatology 53:23-31. IF (2011): 11.665; Lugar: 2/73 Gastroenterology and Hepatology; 1er cuartil.
    ABSTRACT CORTESÍA DE PUBMED

  • Mansilla, C., P. Berraondo, M. Durantez, M. Martinez, N. Casares, L. Arribillaga, F. Rudilla, J. Fioravanti, T. Lozano, L. Villanueva, P. Sarobe, F. Borras, C. Leclerc, J. Prieto, and J. J. Lasarte. 2012. Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain A from fibronectin. Int J Cancer 131:641-651. IF (2012): 6.198; Lugar: 26/191 Oncology; 1er cuartil.
    ABSTRACT CORTESÍA DE PUBMED

  • Echeverria, I., A. Pereboev, L. Silva, A. Zabaleta, J. I. Riezu-Boj, M. Bes, M. Cubero, F. Borras-Cuesta, J.J. Lasarte, J. I. Esteban, J. Prieto, and P. Sarobe. 2011. Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells. Hepatology 54:28-37. IF (2011): 11.665; Lugar: 2/73 Gastroenterology and Hepatology; 1er cuartil.
    ABSTRACT CORTESÍA DE PUBMED

  • Aranda, F., D. Llopiz, N. Diaz-Valdes, J. I. Riezu-Boj, J. Bezunartea, M. Ruiz, M. Martinez, M. Durantez, C. Mansilla, J. Prieto, J. J. Lasarte, F. Borras-Cuesta, and P. Sarobe. 2011. Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors. Cancer Res 71:3214-3224. IF (2011): 7.856; Lugar: 12/192 Oncology; 1er cuartil.
    ABSTRACT CORTESÍA DE PUBMED

  • Mansilla, C., M. Gorraiz, M. Martinez, N. Casares, L. Arribillaga, F. Rudilla, I. Echeverria, J. I. Riezu-Boj, P. Sarobe, F. Borras-Cuesta, J. Prieto, and J. J. Lasarte. 2009. Immunization against hepatitis C virus with a fusion protein containing the extra domain A from fibronectin and the hepatitis C virus NS3 protein. J Hepatol 51:520-527. IF (2009): 7.818; Lugar: 4/65. Gastroenterology and Hepatology; 1er cuartil.
    ABSTRACT CORTESÍA DE PUBMED

Línea Inmunomodulación terapéutica

  • Sangro, B., C. Gomez-Martin, M. de la Mata, M. Inarrairaegui, E. Garralda, P. Barrera, J. I. Riezu-Boj, E. Larrea, C. Alfaro, P. Sarobe, J. J. Lasarte, J. L. Perez-Gracia, I. Melero, and J. Prieto. 2013. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 59:81-88. IF (2012): 9.858; Lugar: 5/73 Gastroenterology and Hepatology; 1er cuartil.
    ABSTRACT CORTESÍA DE PUBMED

  • Morales-Kastresana, A., M. F. Sanmamed, I. Rodriguez, A. Palazon, I. Martinez-Forero, S. Labiano, S. Hervas-Stubbs, B. Sangro, C. Ochoa, A. Rouzaut, A. Azpilikueta, E. Bolanos, M. Jure-Kunkel, I. Gutgemann, and I. Melero. 2013. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. Clin Cancer Res 19:6151-6162. IF (2012): 7.837; Lugar: 12/197 Oncology; 1er cuartil.
    ABSTRACT CORTESÍA DE PUBMED

  • Fioravanti, J., I. Gonzalez, J. Medina-Echeverz, E. Larrea, N. Ardaiz, G. Gonzalez-Aseguinolaza, J. Prieto, and P. Berraondo. 2011. Anchoring interferon alpha to apolipoprotein A-I reduces hematological toxicity while enhancing immunostimulatory properties. Hepatology 53:1864-1873. IF (2011): 11.665; Lugar: 2/73 Gastro- enterology and Hepatology; 1er cuartil. 
    ABSTRACT CORTESÍA DE PUBMED

  • Palazon, A., A. Teijeira, I. Martinez-Forero, S. Hervas-Stubbs, C. Roncal, I. Penuelas, J. Dubrot, A. Mo- rales-Kastresana, J. L. Perez-Gracia, M. C. Ochoa, L. Ochoa-Callejero, A. Martinez, A. Luque, J. Dinchuk, A. Rouzaut, M. Jure-Kunkel, and I. Melero. 2011. Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res 71:801-811. IF (2011): 7.856; Lugar: 12/196 Oncology; 1er cuartil.
    ABSTRACT CORTESÍA DE PUBMED

  • Casares, N., F. Rudilla, L. Arribillaga, D. Llopiz, J. I. Riezu-Boj, T. Lozano, J. Lopez-Sagaseta, L. Guembe, P. Sarobe, J. Prieto, F. Borras-Cuesta, and J. J. Lasarte. 2010. A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice. J Immunol 185:5150-5159. IF (2010): 5.745; Lugar: 20/134 Immunology; 1er cuartil.
    ABSTRACT CORTESÍA DE PUBMED

  • Melero I, Quetglas JI, Reboredo M, Dubrot J, Rodriguez-Madoz JR, Mancheño U, Casales E, Riezu-Boj JI, Ruiz-Guillen M, Ochoa MC, Sanmamed MF, Thieblemont N, Smerdou C, Hervas-Stubbs S. Strict requirement for vector-induced type I interferon in efficacious antitumor responses to virally encoded IL12. Cancer Res. 2015 Feb1;75(3):497-507.
    ABSTRACT CORTESÍA DE PUBMED

  • Hervas-Stubbs S, Mancheño U, Riezu-Boj JI, Larraga A, Ochoa MC, Alignani D, Alfaro C, Morales-Kastresana A, Gonzalez I, Larrea E, Pircher H, Le Bon A, Lopez-Picazo JM, Martín-Algarra S, Prieto J, Melero I. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy. J Immunol. 2012 Oct 1;189(7):3299-310.
    ABSTRACT CORTESÍA DE PUBMED



"Nuestro equipo ha desarrollado moléculas inmunorreguladoras y estrategias de vacunación muy prometedoras que se están evaluando en ensayos clínicos", Dr. Juan José Lasarte, director del programa.

Contacto

Contacto:
Cristina López
Avda. Pío XII, 55
31008 Pamplona
España

(+34) 948 194 700 Ext. 6021
clopezg@unav.es